Dane Leone
Stock Analyst at Raymond James
(1.13)
# 3,749
Out of 4,984 analysts
69
Total ratings
33.96%
Success rate
-9.05%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $4.13 | +360.05% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.77 | +422.40% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $9.26 | +385.96% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $44.70 | -32.89% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $575.06 | +65.20% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $1.95 | +566.67% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $51.49 | -10.66% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $32.02 | +115.49% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $3.61 | +121.61% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $12.44 | +12.59% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $8.62 | +572.85% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $15.43 | +353.66% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.18 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $49.76 | +26.61% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $46.34 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.71 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $50.60 | +28.46% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $273.09 | -6.62% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.25 | +652.94% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $176.46 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $4.13
Upside: +360.05%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.77
Upside: +422.40%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $9.26
Upside: +385.96%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $44.70
Upside: -32.89%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $575.06
Upside: +65.20%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $1.95
Upside: +566.67%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $51.49
Upside: -10.66%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $32.02
Upside: +115.49%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $3.61
Upside: +121.61%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $12.44
Upside: +12.59%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $8.62
Upside: +572.85%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $15.43
Upside: +353.66%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.18
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $49.76
Upside: +26.61%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $46.34
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.71
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $50.60
Upside: +28.46%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $273.09
Upside: -6.62%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.25
Upside: +652.94%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $176.46
Upside: -